Ihsan Gursel

List of Publications by Year
in descending order

70 papers	8,926 citations	34 h-index (117453)	67 g-index (98622)
70 all docs	70 docs citations	70 times ranked	13476 citing authors

#	Article	IF	Citations
1	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	5.5	3,973
2	Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells. Journal of Immunology, 2001, 167, 3555-3558.	0.4	529
3	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	7.3	397
4	Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials, 2016, 105, 195-205.	5.7	286
5	Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews, 2004, 199, 201-216.	2.8	270
6	Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation. Journal of Immunology, 2003, 171, 1393-1400.	0.4	211
7	Antibiotic release from biodegradable PHBV microparticles. Journal of Controlled Release, 1999, 59, 207-217.	4.8	189
8	Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides. Journal of Immunology, 2001, 167, 3324-3328.	0.4	180
9	Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Seminars in Immunology, 2004, 16, 17-22.	2.7	165
10	In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials, 2000, 22, 73-80.	5.7	135
11	Potential Role of Phosphatidylinositol 3 Kinase, rather than DNA-dependent Protein Kinase, in CpG DNAâ€“induced Immune Activation. Journal of Experimental Medicine, 2002, 196, 269-274.	4.2	129
12	Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. Journal of Leukocyte Biology, 2002, 71, 813-20.	1.5	127
13	Intestinal Microbiota in Patients with Spinal Cord Injury. PLoS ONE, 2016, 11, e0145878.	1.1	124
14	Is global BCG vaccinationâ€induced trained immunity relevant to the progression of SARSâ€CoVâ€2 pandemic?. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1815-1819.	2.7	118
15	CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine. Infection and Immunity, 2005, 73, 828-833.	1.0	117
16	Effect of Suppressive DNA on CpG-Induced Immune Activation. Journal of Immunology, 2002, 169, 5590-5594.	0.4	101
17	Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release. Journal of Biomaterials Science, Polymer Edition, 2001, 12, 195-207.	1.9	98
18	Biosorption of phenol and 2-chlorophenol by Funalia trogii pellets. Bioresource Technology, 2009, 100, 2685-2691.	4.8	97

#	Article	IF	Citations
19	Sulbactam-cefoperazone polyhydroxybutyrate-co- hydroxyvalerate (PHBV) local antibiotic delivery system:In vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis. , 1999, 46, 494-503.		96
20	Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock. Journal of Immunology, 2005, 174, 4579-4583.	0.4	84
21	Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism, 2002, 46, 2219-2224.	6.7	81
22	CpG ODN Nanorings Induce IFNÎ± from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity. Science Translational Medicine, 2014, 6, 235ra61.	5.8	81
23	In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods. Journal of Microencapsulation, 2002, 19, 153-164.	1.2	80
24	Liposomes as immunological adjuvants and vaccine carriers. Journal of Controlled Release, 1996, 41, 49-56.	4.8	73
25	CXCL16 Influences the Nature and Specificity of CpG-Induced Immune Activation. Journal of Immunology, 2006, 177, 1575-1580.	0.4	68
26	CpG DNA: recognition by and activation of monocytes. Microbes and Infection, 2002, 4, 897-901.	1.0	64
27	Properties and drug release behaviour of poly(3-hydroxybutyric acid) and various poly(3-hydroxybutyrate-hydroxyvalerate) copolymer microcapsules. Journal of Microencapsulation, 1995, 12, 185-193.	1.2	60
28	Synthesis and mechanical properties of interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate. Biomaterials, 1998, 19, 1137-1143.	5.7	57
29	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	2.8	56
30	In vivo response to biodegradable controlled antibiotic release systems. Journal of Biomedical Materials Research Part B, 2001, 55, 217-228.	3.0	54
31	Immobilization of laccase on itaconic acid grafted and Cu(II) ion chelated chitosan membrane for bioremediation of hazardous materials. Journal of Chemical Technology and Biotechnology, 2012, 87, 530-539.	1.6	53
32	Type I IFNâ€"related NETosis in ataxia telangiectasia and Artemis deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 246-257.	1.5	47
33	Chondroitin sulfateâ€"coated polyhydroxyethyl methacrylate membrane prevents adhesion in full-thickness tendon tears of rabbits. Journal of Hand Surgery, 2002, 27, 293-306.	0.7	46
34	Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development. Journal of Controlled Release, 2017, 247, 134-144.	4.8	45
35	Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials, 2011, 32, 1715-1723.	5.7	43
36	Regulation of CpG-Induced Immune Activation by Suppressive Oligodeoxynucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 112-123.	1.8	33

#	Article	IF	Citations
37	Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response. Journal of Controlled Release, 2020, 328, 587-595.	4.8	33
38	Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cellâ€penetrating peptide or combined with CpG. European Journal of Immunology, 2015, 45, 1170-1179.	1.6	31
39	Human Gut Commensal Membrane Vesicles Modulate Inflammation by Generating M2-like Macrophages and Myeloid-Derived Suppressor Cells. Journal of Immunology, 2020, 205, 2707-2718.	0.4	31
40	CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Molecular Immunology, 2007, 44, 1095-1104.	1.0	30
41	Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Current Opinion in Molecular Therapeutics, 2004, 6, 166-74.	2.8	30
42	Therapeutic Potential of Oligonucleotides Expressing Immunosuppressive TTAGGG Motifs. Annals of the New York Academy of Sciences, 2005, 1058, 87-95.	1.8	27
43	Suppression of <scp>B</scp>â€cell activation and <scp>I</scp>g<scp>E</scp>,<scp> I</scp>g<scp>A</scp>,<scp> I</scp>g<scp>G</scp>1 and <scp>I</scp>g<scp>G</scp>4 production by mammalian telomeric oligonucleotides. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 593-603.	2.7	27
44	Development and preclinical evaluation of virusâ€like particle vaccine against COVIDâ€19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	2.7	27
45	Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clinical Cancer Research, 2003, 9, 6516-22.	3.2	27
46	Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacological Research, 2016, 105, 216-225.	3.1	26
47	Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection. Turkish Journal of Biology, 2020, 44, 273-282.	2.1	24
48	Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. Research in Veterinary Science, 2012, 93, 1261-1265.	0.9	23
49	Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Seminars in Immunopathology, 2000, 22, 173-83.	4.0	23
50	Immunostimulatory activity of polysaccharideâ€“poly(I:C) nanoparticles. Biomaterials, 2011, 32, 4275-4282.	5.7	22
51	Reduction of Surgery-Induced Peritoneal Adhesions by Continuous Release of Streptokinase from a Drug Delivery System. European Surgical Research, 2003, 35, 46-49.	0.6	19
52	3D-MSCs A151 ODN-loaded exosomes are immunomodulatory and reveal a proteomic cargo that sustains wound resolution. Journal of Advanced Research, 2022, 41, 113-128.	4.4	17
53	Immunomodulatory function and in vivo properties of Pediococcus pentosaceus OZF, a promising probiotic strain. Annals of Microbiology, 2013, 63, 1311-1318.	1.1	16
54	Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics, 2021, 13, 501.	2.0	15

#	Article	IF	Citations
55	Development of CpG ODN Based Vaccine Adjuvant Formulations. Methods in Molecular Biology, 2016, 1404, 289-298.	0.4	14
56	Effects of Obesity on Airway and Systemic Inflammation in Asthmatic Children. International Archives of Allergy and Immunology, 2021, 182, 679-689.	0.9	13
57	TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice. Immunology Letters, 2021, 239, 32-41.	1.1	13
58	Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies BehÃ§et's disease severity. Journal of Extracellular Vesicles, 2017, 6, 1284449.	5.5	11
59	A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway. International Immunology, 2020, 32, 39-48.	1.8	10
60	Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction. PLoS ONE, 2017, 12, e0171003.	1.1	9
61	Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings. OncoImmunology, 2014, 3, e950166.	2.1	8
62	Mammalian Telomeric DNA Suppresses Endotoxin-induced Uveitis*. Journal of Biological Chemistry, 2010, 285, 28806-28811.	1.6	7
63	The effects of an insertion in the 5â€²UTR of the AMCase on gene expression and pulmonary functions. Respiratory Medicine, 2011, 105, 1160-1169.	1.3	7
64	Parametrically coupled multiharmonic force imaging. Applied Physics Letters, 2008, 92, .	1.5	4
65	The role of <i>bcsE</i> gene in the pathogenicity of <i>Salmonella</i>. Pathogens and Disease, 2021, 79, .	0.8	4
66	Circulating extracellular vesicles of steroid sensitive nephrotic syndrome patients have higher RAC1 and induce recapitulation of nephrotic syndrome phenotype in podocytes. American Journal of Physiology - Renal Physiology, 2021, 321, F659-F673.	1.3	4
67	Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency. Journal of Clinical Immunology, 2022, 42, 582-596.	2.0	3
68	Plasmacytoid Dendritic Cell Response to CpG ODN Correlates with CXCL16 Expression and Is Inhibited by ox-LDL. Mediators of Inflammation, 2013, 2013, 1-7.	1.4	2
69	Antibiotic Release from Biodegradable PHBV Microparticles. , 1998, , 89-96.		2
70	ADMINISTRATION OF BONE MARROW DERIVED MESENCHYMAL STEM CELLS MODULATE TLR EXPRESSION DURING LIVER REGENERATION. Trakya University Journal of Natural Sciences, 0, 20, 1-10.	0.4	0